

Environmental and Social Data Sheet

Overview

Project Name:	ONCOPEPTIDES (EGFF)
Project Number:	2020-0235
Country:	Sweden
Project Description:	Quasi equity financing to Oncopeptides - publicly listed Swedish biotech developing targeted therapies for difficult-to-treat haematological diseases such as Relapsed and Refractory Multiple Myeloma.
EIA required:	no
Project included in Carbon Footprint Exercise ¹ :	no

Environmental and Social Assessment

Environmental Assessment

The activities to be financed are research, development and innovation in the pharmaceutical sector which are a central part of the promoter's operations and will be embedded in the existing organisational and management structure

The project's activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU, and the research activities will be executed in existing and authorised research facilities. Therefore, an Environmental Impact Assessment (EIA) is not required.

The promoter's practices are in compliance with the relevant national and EU regulations (directives 2001/83/EC, 2005/28/EC, 2001/20/EC and applicable good practice quality guidelines and regulations). The promoter maintains adequate internal procedures and management practices that are in line with industry standards and are subjected to regular external audits.

Other Environmental and Social Aspects

The project, if successful, is expected to lead to important social benefits, improving the lives of patients suffering from difficult-to-treat haematological diseases.

The promoter is committed to animal welfare and the responsible use of animals for scientific purposes. Moreover, the promoter complies with the European Directive 2010/63/EU on the protection of animals used for scientific purposes, where applicable.

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.

Luxembourg, 21.08.2020

Conclusions and Recommendations

The project concerns investments in research and development that will be carried out in existing facilities without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required under EIA Directive 2014/52/EU amending Directive 2011/92/EU. The promoter has effective policies and operating procedures in place, which are in line with industry standards.

The research activities undertaken in the project aim to result in new medicinal products with a significant impact on healthcare. Therefore, if the project is successful, it is expected to have a positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects.